Skip to content
10-K

Annual Report

Adaptive Biotechnologies Corp ADPT

0000950170-25-030913

← back to feed
Filed
Mar 3, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 26, 2025 148.58M sh
Long Term Debt FY 2024 · Dec 31, 2023 $130.66M
Cash And Equivalents FY 2024 · Dec 31, 2023 $65.06M
Stockholders Equity FY 2024 · Dec 31, 2023 $308.4M
Current Liabilities FY 2024 · Dec 31, 2023 $88.02M
Total Liabilities FY 2024 · Dec 31, 2023 $352.86M
Current Assets FY 2024 · Dec 31, 2023 $410.19M
Total Assets FY 2024 · Dec 31, 2023 $661.13M
Shares Diluted FY 2024 · Dec 31, 2022 142.52M sh
Capex FY 2024 · Dec 31, 2022 $16.35M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$183.95M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.40
Eps Basic FY 2024 · Dec 31, 2022 −$1.40
Sga Expense FY 2024 · Dec 31, 2022 $88.53M
Rd Expense FY 2024 · Dec 31, 2022 $141.76M
Net Income FY 2024 · Dec 31, 2022 −$200.19M
Operating Income FY 2024 · Dec 31, 2022 −$200.19M
Cost Of Revenue FY 2024 · Dec 31, 2022 $57.91M
Revenue FY 2024 · Dec 31, 2022 $185.31M